Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort

Although hypomethylating agents (HMAs) are frequently used in the frontline treatment of older acute myeloid leukemia (AML) patients, little is known about their effectiveness in relapsed or primary treatment–refractory (RR)-AML. Using an international multicenter retrospective database, we studied...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Blood Adv
Huvudupphovsmän: Stahl, Maximilian, DeVeaux, Michelle, Montesinos, Pau, Itzykson, Raphael, Ritchie, Ellen K., Sekeres, Mikkael A., Barnard, John D., Podoltsev, Nikolai A., Brunner, Andrew M., Komrokji, Rami S., Bhatt, Vijaya R., Al-Kali, Aref, Cluzeau, Thomas, Santini, Valeria, Fathi, Amir T., Roboz, Gail J., Fenaux, Pierre, Litzow, Mark R., Perreault, Sarah, Kim, Tae Kon, Prebet, Thomas, Vey, Norbert, Verma, Vivek, Germing, Ulrich, Bergua, Juan Miguel, Serrano, Josefina, Gore, Steven D., Zeidan, Amer M.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Hematology 2018
Ämnen:
Myeloid Neoplasia
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5916007/
https://ncbi.nlm.nih.gov/pubmed/29685952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018016121
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk